triazoles has been researched along with Metastase in 140 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (1.43) | 18.7374 |
| 1990's | 11 (7.86) | 18.2507 |
| 2000's | 46 (32.86) | 29.6817 |
| 2010's | 76 (54.29) | 24.3611 |
| 2020's | 5 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Asim, M; Ateeq, B; Bhatia, V; Biswas, T; Carskadon, S; Goel, S; Gupta, N; Kundu, S; Morrissey, C; Palanisamy, N | 1 |
| Akca, H; Alvur, O; Baygu, Y; Gok, Y; Kabay, N; Kucuksayan, H | 1 |
| Engelbrecht, AM; Joubert, AM; Mqoco, T; Stander, A | 1 |
| Amberg, S; Bokemeyer, C; Kranich, AL; Mann, J; Nilsson, S; Papadimitriou, K; Rolfo, C; Stein, A; Theile, S | 1 |
| Cho, HY; Jeon, YH; Kim, GW; Kim, SY; Kwon, SH; Lee, DH; Lee, SW; Yoo, J | 1 |
| Chen, YJ; Ding, JC; Hu, GS; Hu, YH; Liu, JY; Liu, W; Xia, L; Xia, NS; Zheng, ZZ | 1 |
| Kim, ES; Scott, LJ | 1 |
| Chen, H; Chen, Z; Du, Y; Guo, J; Liu, X; Tan, Y; Wang, L; Wang, M; Wang, X; Weng, X | 1 |
| Abid, M; Alajmi, MF; Ali, S; Aneja, B; El-Seedi, HR; Hassan, MI; Hussain, A; Khan, NS; Khan, P; Queen, A; Rehman, MT | 1 |
| Altwerger, G; Ardighieri, L; Azodi, M; Bellone, S; Bianchi, A; Bignotti, E; Bonazzoli, E; Buza, N; Choi, J; Dong, W; Han, C; Huang, GS; Hui, P; Li, C; Lifton, RP; Litkouhi, B; Lopez, S; Manara, P; Manzano, A; Menderes, G; Odicino, F; Pecorelli, S; Pettinella, F; Ratner, E; Ravaggi, A; Riccio, F; Romani, C; Santin, AD; Schlessinger, J; Schwartz, PE; Silasi, DA; Todeschini, P; Wong, S; Yadav, G; Yang-Hartwich, Y; Zammataro, L; Zanotti, L; Zeybek, B; Zizioli, V | 1 |
| Boulware, D; Extermann, M; Goodridge, D; Han, HS; Hogue, D; Ismail-Khan, R; Khong, H; Shafique, M; Soliman, H; Sullivan, D | 1 |
| Chen, Y; Guo, W; He, Y; Krimm, I; Li, Y; Liu, M; Mi, D; Pei, H; Shao, T; Wang, P; Wang, X; Yi, Z; Zhang, Y | 1 |
| Bullova, P; Giubellino, A; Landau, M; Lee, MJ; Neckers, L; Pacak, K; Scroggins, B; Sourbier, C; Trepel, JB; Ying, W | 1 |
| Baer, C; Breyssens, H; Brown, NR; Caballero, OL; Cebon, J; Endicott, J; Goding, CR; Hu, Y; John, T; Jones, EY; Kessler, BM; Knapp, S; Lu, M; Lu, X; Middleton, MR; Ratnayaka, I; Salter, V; Siebold, C; Sullivan, A; Sviderskaya, EV; Zhong, S | 1 |
| Alumkal, J; Bottomly, D; Coleman, I; Gao, L; Gibbs, A; Kleinschmidt, R; Lisac, R; McWeeney, S; Nelson, P; Schwartzman, J; Wilmot, B | 1 |
| Bliss, JM; Braybrooke, JP; Brunt, AM; Cameron, D; Cheung, KL; Coombes, G; Dodwell, D; Dowsett, M; Ellis, P; Folkerd, E; Hayward, L; Howell, A; Im, YH; Johnston, SR; Jyothirmayi, R; Kilburn, LS; Robinson, A; Sergenson, N; Sin, HJ; Wardley, AM; Wheatley, D | 1 |
| Beavis, PA; Chow, MT; Darcy, PK; Devaud, C; Divisekera, U; Dwyer, K; John, LB; Paget, C; Smyth, MJ; Stagg, J | 1 |
| Bachner, M; Brase, JC; Dietze, O; Dubsky, P; Filipits, M; Fisch, K; Gehrmann, MC; Gnant, M; Greil, R; Jakesz, R; Klug, E; Kronenwett, R; Luisser, I; Mayr, D; Petry, C; Rudas, M; Schmidt, M; Sedivy, R; Singer, CF; Weber, KE | 1 |
| Acquaviva, J; Bates, RC; El-Hariry, I; He, S; Jimenez, JP; Nagai, M; Proia, DA; Sang, J; Sequeira, M; Shapiro, GI; Smith, DL; Spector, N; Tolaney, S; Zhang, C | 1 |
| Dering, J; Ellis, C; Finn, RS; Florance, A; Johnston, S; Martin, AM; O'Rourke, L; Press, MF | 1 |
| Chaturvedi, P; Gilkes, DM; Hu, H; Liang, H; Luo, W; Semenza, GL; Takano, N; Xiang, L | 1 |
| Bonnefoi, H; Coates, AS; Cole, BF; Colleoni, M; Ejlertsen, B; Forbes, JF; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Huober, J; Láng, I; Neven, P; Price, KN; Rabaglio, M; Smith, I; Thürlimann, B; Wardley, A; Wu, J | 1 |
| Nakamura, H; Yoneyama, K | 1 |
| Chai, J; Chen, D; Cheng, X; Jia, S; Li, T; Liang, L; Shen, Z; Sun, M; Yang, X | 1 |
| Bradner, JE; Castillo-Martin, M; Cho, H; Cordon-Cardo, C; Herzka, T; Qi, J; Robinson, BD; Trotman, LC; Wilkinson, JE; Zheng, W | 1 |
| Carpi, A; Ferrari, P; Nicolini, A; Rossi, G | 1 |
| Bauman, L; Chandarlapaty, S; D'Andrea, G; Drullinsky, P; El-Hariry, I; Fasano, J; Gilewski, T; Goldfarb, S; Haque, S; Hudis, C; Jhaveri, K; Lake, D; Lim, K; Modi, S; Moynahan, ME; Patil, S; Reddington, L; Robson, M; Sugarman, S; Vukovic, V; Wasserheit-Leiblich, C | 1 |
| Andrews, C; Carpenter, R; Cordiner, C; Doughty, JC; Ellis, G; Gandhi, A; Gui, G; Moss, N; Skene, AI; Wilson, C | 1 |
| Campos-Gómez, S; Chapa-Ibargüengoitia, M; de la Peña-Lopez, R; Dorantes-Heredia, R; Flores-Arredondo, JH | 1 |
| Addis, A; Di Cesare, E; Festuccia, C; Gravina, GL; Kauffman, M; Landesman, Y; Lenzi, A; Mancini, A; McCauley, D; Shacham, S; Tortoreto, M; Zaffaroni, N | 1 |
| Armengol-Alonso, A; Dalmau, E; Muñoz, M; Seguí-Palmer, MÁ | 1 |
| Fearnley, GW; Fishwick, CW; Gage, MC; Homer-Vanniasinkam, S; Kankanala, J; Kearney, MT; Latham, AM; Ponnambalam, S; Wheatcroft, SB | 1 |
| Capanu, M; Cercek, A; Chou, JF; Gollub, M; Proia, DA; Raasch, P; Reidy-Lagunes, D; Saltz, LB; Shia, J; Solit, DB; Vakiani, E | 1 |
| Bae-Jump, VL; Chan, LL; Gehrig, PA; Jackson, AL; Kilgore, JE; Qiu, H; Zhong, Y; Zhou, C | 1 |
| Gao, L; Kannan, A; Kern, M; Moreno, MA; Sengupta, D; Stack, B; Suen, JY; Tackett, AJ; Vural, E | 1 |
| Henry, NL; Morikawa, A | 1 |
| Chen, H; Ding, HF; Dong, Z; Fang, D; Huang, S; Jing, Q; Lu, Y; Su, SB; Yang, L | 1 |
| Bainer, R; Becker, L; Chada, K; Frankenberger, C; Gilad, Y; Krausz, T; Rabe, D; Rosner, MR; Sankarasharma, D | 1 |
| Abrial, C; Arbre, M; Chollet, P; Devaud, H; Dohou, J; Dubray-Longeras, P; Durando, X; Herviou, P; Kwiatkowski, F; Mahammedi, H; Mouret-Reynier, MA; Planchat, E; Pouget, M; Van Praagh, I | 1 |
| Antonarakis, ES; Dzinic, SH; Freeman, S; Heath, EI; Heilbrun, LK; Li, X; Liu, G; Sheng, S; Smith, D; Stein, M; Thakur, MK; Vaishampayan, U | 1 |
| Calvo, F; Chakravarty, P; Del Pozo Martin, Y; Derzsi, S; Hill, CS; Malanchi, I; Ombrato, L; Park, D; Ramachandran, A; Sahai, E; Spencer-Dene, B | 1 |
| Babilonti, L; Bogliolo, S; Cassani, C; De Silvestri, A; Dominoni, M; Gaggero, CR; Gardella, B; Musacchi, V; Spinillo, A; Zanellini, F | 1 |
| Cui, S; Lü, H; Niu, L; Yan, M; Zeng, H; Zhang, M | 1 |
| Ahirwar, DK; Ganju, RK; Li, DY; Nasser, MW; Oghumu, S; Powell, CA; Satoskar, AR; Wilkie, T; Zhao, H | 1 |
| Beauchemin, C; Lachaine, J; Letarte, N; Mathurin, K; Yelle, L | 1 |
| Furukawa, S; Handa, H; Hashimoto, A; Hashimoto, S; Mikami, S; Oikawa, T; Okada, Y; Onodera, Y; Oya, M; Sabe, H; Sugino, H; Yoshikawa, A | 1 |
| Berishaj, M; Bonafé, M; Bowman, RL; Bromberg, J; Ceccarelli, C; Chang, Q; Chen, J; Colameco, C; Cricca, M; Daly, L; DeMichele, A; Fabbri, N; Feldman, M; Gasparre, G; Healey, JH; Lyden, D; Mao, JJ; Nnoli, J; Perna, F; Rajasekhar, VK; Sansone, P; Santini, D; Shih, NN; Taffurelli, M; Vidone, M | 1 |
| Fan, S; Fang, J; Gu, D; Jin, H; Qin, W; Tao, X; Wang, C; Wang, N; Wang, Y; Wei, L; Yao, M; Zhang, Y; Zhao, F | 1 |
| Bielski, CM; Boehm, JS; Cheah, JH; Church, AJ; Cima, MJ; Clemons, PA; Cowley, GS; Crompton, BD; Doshi, MB; Garraway, LA; Gill, S; Hahn, WC; Hong, AL; Howell, S; Imamovic, A; Janeway, KA; Jonas, O; Keskula, P; Kryukov, GV; Kynnap, BD; Langer, RS; Meyer, SC; Oh, C; Roberts, CW; Rodriguez-Galindo, C; Root, DE; Schreiber, SL; Shamji, AF; Stegmaier, K; Tseng, YY; Tsherniak, A; van Hummelen, P; Vazquez, F | 1 |
| Arellano, C; Chatelut, E; Dalenc, F; Filleron, T; Iuliano, L; Marquet, P; Poirot, M; Roché, H; Samadi, M; Silvente-Poirot, S; Voisin, M; Zerbinati, C | 1 |
| Beom, SH; Han, SW; Han, W; Im, SA; Kim, TY; Lee, KH; Moon, HG; Noh, DY; Oh, DY; Oh, J; Suh, KJ; Yang, Y | 1 |
| Basik, M; Clemons, M; Cristofanilli, M; Dreosti, L; Grzeda, L; Hegg, R; Johnston, S; Lausoontornsiri, W; Mann, H; Stuart, M | 1 |
| Allred, DC; Babiera, G; Barnes, M; Brink, A; Budd, GT; Carey, L; Creighton, CJ; Crouch, E; Dayao, Z; DeSchryver, K; Dowsett, M; Ellis, MJ; Esserman, L; Goncalves, R; Guenther, JM; Hoog, J; Hunt, K; Leitch, M; Luo, J; Ma, CX; Olson, JA; Ota, D; Pluard, T; Sanati, S; Silverman, P; Suman, VJ; Tao, Y; Unzeitig, G; Watson, M; Whitworth, P; Winer, E | 1 |
| Jeong, DK; Kumari, S; Mishra, CB; Mongre, RK; Tiwari, M | 1 |
| Klinge, CM; Muluhngwi, P | 1 |
| Chen, B; Chen, S; Evans, DB; Lisztwan, J; Pornon, A | 1 |
| Fabi, A; Metro, G; Mottolese, M | 1 |
| Harbeck, N | 1 |
| Cianfrocca, M | 1 |
| Cheung, KL; Haynes, AP; Wood, JP | 1 |
| Wardley, AM | 1 |
| Barker, LC; Brand, IR; Crawford, SM | 1 |
| Bapsy, PP; Clemens, MR; Feyereislova, A; Jahn, M; Jones, A; Kaufman, B; Lehle, M; Mackey, JR; Révil, C; Tjulandin, S; Vaid, A; Wardley, A | 1 |
| Liu, S; Redman, CW; Todd, RW; Tzakas, E | 1 |
| Doyen, J; Ferrero, JM; Fontana, X; Italiano, A; Largillier, R; Thyss, A | 1 |
| Colleoni, M; Dellapasqua, S | 1 |
| Apatira, A; Brandt, R; Chang, B; Chua, J; Ding, P; Duan, M; Franci, C; Goff, D; Heckrodt, TJ; Hitoshi, Y; Holland, SJ; Hu, Y; Li, W; Pan, A; Payan, DG; Pine, P; Singh, R; Torneros, A; Yu, J; Zhang, J | 1 |
| Anderson, E; Arena, FP; Bacus, S; Cora, EM; Cristofanilli, M; Curcio, E; Kroener, JF; Magill, PJ; Mangalik, A; Rabinowitz, I; Royce, M; Valero, V; Watkins, C | 1 |
| Jung, SY; Kang, HS; Kim, EA; Kim, SW; Kwon, Y; Lee, KS; Lee, S; Nam, BH; Park, IH; Ro, J | 1 |
| Arron, ST; Ibrahim, SF; Singer, JP | 1 |
| Curran, MP | 1 |
| Arun, B; Carlson, RW; Chiv, VY; Chung, CT; Dice, K; Green, M; Phan, SC; Rivera, E; Schurman, CM; Theriault, R; Valero, V | 1 |
| Chetver, L; Hussein, O; Zidan, J; Zucker, M | 1 |
| Dobbins, TA; Drew, AK; Harris, CA; Pearson, S; Ward, RL | 1 |
| Doughty, JC | 2 |
| Kusama, M | 1 |
| Chu, QS; Steed, HL | 1 |
| Hong, SH; Jeong, J; Kim, SY; Lee, H; Lee, KS; Lee, YS; Nam, BH; Park, IH; Ro, J | 1 |
| Arrowsmith, E; Barton, J; Burris, HA; Clark, BL; Hainsworth, JD; Rubin, M; Shipley, D; Yardley, DA | 1 |
| Bathini, V; Buttar, A; Khan, A; Mittal, K | 1 |
| Acton, G; Alyasova, A; Bondarenko, I; Chau, A; Erlandsson, F; Ibrahim, NK; Jones, D; Komisarenko, V; Manikhas, A; Murray, JL; Pegram, M; Semiglazov, V; Senderovich, S; Shparyk, Y; Yariz, KO | 1 |
| Cruz Jurado, J; Fernández Martínez, R; Galve Calvo, E; García Mata, J; García Palomo, A; Murillo Jaso, L; Peláez Fernández, I; Polo Marqués, E; Richart Aznar, P; Sampedro Gimeno, T | 1 |
| Anesini, C; Avanzo, RE; D'Accorso, NB; Errea, MI; Fascio, ML | 1 |
| Badve, SS; Carlson, RW; Gomez, HL; O'Neill, A; Sledge, GW; Vidaurre, T | 1 |
| Alkaied, H; Awasum, M; Brenner, A; Harris, K; Varma, S | 1 |
| De La Fuente, M; Ertel, A; Jiao, X; Lisanti, MP; Pestell, RG; Pestell, TG; Velasco-Velázquez, M | 1 |
| Amonkar, MM; Diaz, JR; Forbes, CA; Kleijnen, J; Lykopoulos, K; Rea, DW; Riemsma, R | 1 |
| Albain, KS; Barlow, WE; Dakhil, SR; Gralow, JR; Hayes, DF; Hortobagyi, GN; Lew, DL; Livingston, RB; Mehta, RS; Tirumali, NR; Vandenberg, TA | 1 |
| Ford, SJ; Jansson, PJ; Kalinowski, DS; Kovacevic, Z; Lovejoy, DB; Lui, GY; Obeidy, P; Richardson, DR; Sharp, DM; Tselepis, C | 1 |
| Berkenblit, A; Bondarenko, I; Brincat, S; Chan, A; Chow, L; Cincotta, M; Fumoleau, P; Garin, AM; Guimaraes, RC; Hachemi, S; Hayes, DF; Kang, LL; Krygowski, M; Lazar, AA; Moore, L; Neskovic-Konstantinovic, Z; Strahs, A; Sun, Y; Wolff, AC | 1 |
| Burton, G; Buzdar, A; Come, S; Dimery, I; Elledge, R; Ellis, M; Gertler, SZ; Jones, SE; May, JT; Morris, C; Osborne, CK; Parker, LM; Pippen, J; Webster, A | 1 |
| Aschermannova, A; Erikstein, B; Howell, A; Kleeberg, UR; Mauriac, L; Morris, C; Quaresma Albano, J; Robertson, JF; Vergote, I; Webster, A | 1 |
| Atalay, G; Cardoso, F; Piccart, MJ | 1 |
| Miyoshi, Y; Noguchi, S; Taguchi, T; Tamaki, Y | 1 |
| Ali, SM; Brady, C; Carney, W; Chaudri-Ross, HA; Demers, L; Harvey, HA; Leitzel, K; Lipton, A; Wyld, P | 1 |
| Brodie, AH; Mouridsen, HT | 1 |
| Rose, C | 1 |
| Carlini, P; Cognetti, F; Colella, E; Di Cosimo, S; Fabi, A; Ferretti, G; Frassoldati, A; Papaldo, P; Romiti, A; Ruggeri, EM; Tomao, S; Tonachella, R | 1 |
| Konovalova, NP | 1 |
| BISAGNI, E; ENNUYER, A; ROYER, R; ZAJDELA, F | 1 |
| Gershanovich, M; Mouridsen, H | 1 |
| Carlson, RW; Henderson, IC | 1 |
| Altundag, K; Altundag, O | 1 |
| Howell, A; Robertson, JF; Vergote, I | 1 |
| Curran, MP; McKeage, K; Plosker, GL | 1 |
| Ferrero, JM; Foa, C; Hartmann, MT; Italiano, A; Largillier, R; Marcy, PY; Namer, M | 1 |
| Becquart, D; Chaudri-Ross, HA; Gershanovich, M; Lang, R; Mouridsen, H; Perez-Carrion, R; Sun, Y | 1 |
| Hirono, M; Ikeda, M; Kurebayashi, J; Nakashima, K; Nomura, T; Okubo, S; Sonoo, H; Tanaka, K; Udagawa, K | 1 |
| Mouridsen, HT | 1 |
| Carpi, A; Nicolini, A | 1 |
| Ponzone, R; Sismondi, P | 1 |
| Ang, P; Chia, WK; Greaves, MW; Lim, YL | 1 |
| Bhatnagar, AS | 1 |
| Abrial, C; Cabrespine, A; Chollet, P; Cure, H; Durando, X; Ferriere, JP; Kwiatkowski, F; Leheurteur, M; Mouret-Reynier, MA; Penault-Llorca, F | 1 |
| Langenegger, T; Schiesser, D; Thürlimann, B; Wahl, P | 1 |
| Brandman, J; Delea, TE; Gross, PE; Johnston, SR; Karnon, J; Smith, RE; Sung, JC | 1 |
| El-Hajj, II; El-Saghir, NS; Makarem, JA; Otrock, ZK | 1 |
| Ali, SM; Carney, W; Chaudri-Ross, HA; Demers, L; Evans, DB; Hackl, W; Hamer, P; Leitzel, K; Lipton, A; Souder, C | 1 |
| Alba, E; Barnadas, A; Colomer, R; Constenla, M; Fernández, R; Gil, M; Gilabert, M; Llombart-Cussac, A; Lloveras, B; Mayordomo, JI; Ramos, M; Tusquets, I | 1 |
| Blackwell, KL; Herold, CI | 1 |
| Ikeda, M; Kurebayashi, J; Miyake, A; Nakashima, K; Nomura, T; Shiiki, S; Sonoo, H; Tanaka, K; Yamamoto, Y | 1 |
| Adlercruetz, H; Brady, C; Demers, LM; Grossberg, H; Harvey, HA; Kambic, KB; Lipton, A; Santen, RJ; Trunet, PF | 1 |
| Clavel, M; Decoster, G; Holdener, EE; Klepp, O; Ludwig, C; Pinedo, HM; Renard, G; Sessa, C; Siegenthaler, P; ten Bokkel Huinink, W | 1 |
| Bai, S; Chun, SB; Chung, KC; Ha, TY; Im, SY; Kang, HS; Kim, JW; Ko, HM; Lee, HB; Lee, HK; Lee, YB; Oh, SJ | 1 |
| Buzdar, AU; Hortobagyi, GN; Plourde, PV | 1 |
| Camoriano, JK; Gerstner, JB; Gesme, DH; Hartmann, LC; Hatfield, AK; Ingle, JN; Johnson, PA; Loprinzi, CL; Mailliard, JA; Suman, VJ | 1 |
| Kagiya, TV; Konovalova, NP; Kotelnikova, RA; Tatyanenko, LV; Volkova, LM; Yakushchenko, TN | 1 |
| Ambus, U; Bruynseels, J; Clark, RM; Crump, M; De Coster, R; Goss, PE; Tye, LM; Wadden, NA; Walde, D; Weizel, HA | 1 |
| Hamilton, A; Piccart, M | 1 |
| Bu, W; Li, XM; Qin, LX; Tang, ZY; Xia, JL | 1 |
| Huff, JL; Plopper, GE; Rust, WL | 1 |
| Cappellini, GC; Casali, A; Casali, M; Giuntini, T; Sega, FM; Terzoli, E | 1 |
| Cattel, F; Messori, A; Trippoli, S; Vaiani, M | 1 |
| Burstein, HJ; Winer, EP | 1 |
| Joy, AA; Mackey, JR | 1 |
| Alba, E; Colla, F; Farina, C; Mazzoleni, A; Ragonesi, G | 1 |
| Kohn, EC; Liotta, LA | 1 |
| Bremer, K; Donhujsen-Ant, R; Peukert, M; Possinger, K; Queisser, W; Wagner, H | 1 |
31 review(s) available for triazoles and Metastase
| Article | Year |
|---|---|
Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Triazoles | 2017 |
Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Neoplasm Metastasis; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2014 |
Effectiveness of aromatase inhibitors in the treatment of advanced endometrial adenocarcinoma.
Topics: Adenocarcinoma; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Treatment Outcome; Triazoles | 2016 |
Identification of miRNAs as biomarkers for acquired endocrine resistance in breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Exosomes; Female; Gene Expression Regulation, Neoplastic; Humans; Letrozole; MicroRNAs; Neoplasm Invasiveness; Neoplasm Metastasis; Nitriles; Signal Transduction; Tamoxifen; Triazoles | 2017 |
HER-2-positive metastatic breast cancer: trastuzumab and beyond.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Disease Progression; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Letrozole; Neoplasm Metastasis; Nitriles; Receptor, ErbB-2; Trastuzumab; Triazoles; Vinblastine; Vinorelbine | 2008 |
Never too late: reducing late breast cancer relapse risk.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Europe; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Risk Factors; Tamoxifen; Time Factors; Triazoles | 2008 |
Overcoming recurrence risk: extended adjuvant endocrine therapy.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Lymphatic Metastasis; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2008 |
Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Research Design; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2008 |
Letrozole.
Topics: Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Neoadjuvant Therapy; Neoplasm Metastasis; Nitriles; Postmenopause; Triazoles | 2010 |
Lapatinib: in postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; ErbB Receptors; Female; Humans; Lapatinib; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Triazoles | 2010 |
The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis.
Topics: Anastrozole; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Letrozole; Neoplasm Metastasis; Nitriles; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome; Triazoles | 2011 |
When to start an aromatase inhibitor: now or later?
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Drug Administration Schedule; Female; Humans; Letrozole; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2011 |
Aromatase inhibition: a potential target for the management of recurrent or metastatic endometrial cancer by letrozole: more questions than answers?
Topics: Aromatase Inhibitors; Clinical Trials as Topic; Endometrial Neoplasms; Female; Humans; Letrozole; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Triazoles | 2011 |
Management of patients with metastatic breast cancer.
Topics: Adult; Age Factors; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Disease Management; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Estradiol; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Nitriles; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome; Triazoles | 2011 |
Does hormonal therapy have a therapeutic role in metastatic primary small cell neuroendocrine breast carcinoma? Case report and literature review.
Topics: Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Neuroendocrine; Carcinoma, Small Cell; Combined Modality Therapy; Female; Humans; Letrozole; Neoplasm Metastasis; Nitriles; Triazoles | 2012 |
Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Disease Progression; Female; Humans; Lapatinib; Letrozole; Neoadjuvant Therapy; Neoplasm Metastasis; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Cytoplasmic and Nuclear; Triazoles | 2012 |
Current status of endocrine therapy for breast cancer.
Topics: Algorithms; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Chemotherapy, Adjuvant; Climacteric; Female; Goserelin; Humans; Neoplasm Metastasis; Nitriles; Tamoxifen; Triazoles | 2003 |
Applicability of the intratumor aromatase preclinical model to predict clinical trial results with endocrine therapy.
Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Estrogen Antagonists; Humans; Letrozole; Neoplasm Metastasis; Nitriles; Tamoxifen; Triazoles; Xenograft Model Antitumor Assays | 2003 |
A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Megestrol Acetate; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles | 2003 |
The role of aromatase inhibitors in the treatment of metastatic breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Triazoles | 2003 |
Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Administration Schedule; Endocrine System; Female; Humans; Menopause; Neoplasm Metastasis; Nitriles; Patient Selection; Receptors, Estrogen; Tamoxifen; Triazoles | 2003 |
A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; Humans; Liver Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Treatment Outcome; Triazoles | 2003 |
Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2004 |
Aromatase inhibitors in advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Neoplasm Metastasis; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Triazoles | 2004 |
Review of the development of letrozole and its use in advanced breast cancer and in the neoadjuvant setting.
Topics: Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Drug Administration Schedule; Female; Humans; Letrozole; Neoadjuvant Therapy; Neoplasm Metastasis; Nitriles; Salvage Therapy; Triazoles | 2006 |
The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Evidence-Based Medicine; Letrozole; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Quality of Life; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
A review of the BIG results: the Breast International Group 1-98 trial analyses.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Letrozole; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Quality of Life; Tamoxifen; Treatment Outcome; Triazoles; United States | 2008 |
The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Belgium; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Severity of Illness Index; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 1999 |
Survival in patients with metastatic breast cancer: analysis of randomized studies comparing oral aromatase inhibitors versus megestrol.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Megestrol; Neoplasm Metastasis; Nitriles; Proportional Hazards Models; Randomized Controlled Trials as Topic; Survival Analysis; Triazoles | 2000 |
New combinations with Herceptin in metastatic breast cancer.
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Deoxycytidine; Doxorubicin; Drug Interactions; Drug Synergism; Epirubicin; Female; Fluorouracil; Gemcitabine; Heart Diseases; Hematologic Diseases; Humans; Methotrexate; Neoplasm Metastasis; Nitriles; Organoplatinum Compounds; Paclitaxel; Tamoxifen; Thiotepa; Trastuzumab; Treatment Outcome; Triazoles; Vinblastine; Vinorelbine | 2001 |
[Antiestrogen therapy in the treatment of breast neoplasms].
Topics: Adult; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; Estrogen Antagonists; Female; Forecasting; Humans; Indoles; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Toremifene; Triazoles | 2002 |
29 trial(s) available for triazoles and Metastase
| Article | Year |
|---|---|
Selinexor (KPT-330), an Oral Selective Inhibitor of Nuclear Export (SINE) Compound, in Combination with FOLFOX in Patients with Metastatic Colorectal Cancer (mCRC) - Final Results of the Phase I Trial SENTINEL.
Topics: Active Transport, Cell Nucleus; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Hydrazines; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Prognosis; Survival Rate; Triazoles | 2020 |
A Phase II Trial of Selinexor (KPT-330) for Metastatic Triple-Negative Breast Cancer.
Topics: Adult; Aged; Antineoplastic Agents; Female; Follow-Up Studies; Humans; Hydrazines; Middle Aged; Neoplasm Metastasis; Prognosis; Survival Rate; Triazoles; Triple Negative Breast Neoplasms | 2019 |
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentr
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Disease-Free Survival; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasm Metastasis; Nitriles; Postmenopause; Receptors, Estrogen; Triazoles | 2013 |
A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Female; HSP90 Heat-Shock Proteins; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Triazoles | 2014 |
Optimum duration of neoadjuvant letrozole to permit breast conserving surgery.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Time Factors; Treatment Outcome; Triazoles | 2014 |
Ganetespib, a novel Hsp90 inhibitor in patients with KRAS mutated and wild type, refractory metastatic colorectal cancer.
Topics: Adult; Aged; Biomarkers, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Follow-Up Studies; HSP90 Heat-Shock Proteins; Humans; Immunoenzyme Techniques; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Salvage Therapy; Survival Rate; Triazoles | 2014 |
A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Docetaxel; HSP90 Heat-Shock Proteins; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome; Triazoles | 2016 |
Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; ErbB Receptors; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Retreatment; Signal Transduction; Treatment Outcome; Triazoles | 2016 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Decision-Making; Female; Follow-Up Studies; Humans; Ki-67 Antigen; Letrozole; Middle Aged; Mitotic Index; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Transcriptome; Triazoles | 2017 |
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Prognosis; Proportional Hazards Models; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Statistics, Nonparametric; Survival Analysis; Trastuzumab; Treatment Outcome; Triazoles | 2009 |
Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; ErbB Receptors; Female; Gefitinib; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Prospective Studies; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Tissue Distribution; Treatment Outcome; Triazoles | 2010 |
Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Density; Breast Neoplasms; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Goserelin; Humans; Immunohistochemistry; Injections, Subcutaneous; Kaplan-Meier Estimate; Letrozole; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Postmenopause; Premenopause; Probability; Prognosis; Proportional Hazards Models; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Treatment Outcome; Triazoles | 2010 |
Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Goserelin; Humans; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Premenopause; Triazoles | 2010 |
Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research Consortium.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Estradiol; Female; Fulvestrant; Hormone Replacement Therapy; Humans; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Receptors, Estrogen; Triazoles | 2011 |
Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Immunoglobulin Allotypes; Letrozole; Middle Aged; Mucin-1; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Receptors, Estrogen; Receptors, IgG; Receptors, Progesterone; Triazoles | 2011 |
A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Fulvestrant; Gefitinib; Humans; Middle Aged; Neoplasm Metastasis; Nitriles; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Treatment Outcome; Triazoles | 2012 |
Combination anastrozole and fulvestrant in metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cross-Over Studies; Disease-Free Survival; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Triazoles | 2012 |
Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Placebos; Postmenopause; Sirolimus; Treatment Outcome; Triazoles | 2013 |
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Nitriles; North America; Postmenopause; Quality of Life; Survival Rate; Triazoles | 2002 |
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Logistic Models; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Quality of Life; Survival Rate; Triazoles | 2002 |
Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Estrogen Antagonists; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Receptor, ErbB-2; Switzerland; Tamoxifen; Treatment Outcome; Triazoles; United States | 2003 |
Is there a benefit by the sequence anastrozole-formestane for postmenopausal metastatic breast cancer women?
Topics: Adult; Aged; Anastrozole; Androstenedione; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles | 2003 |
Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Female; Humans; Karnofsky Performance Status; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Beta-interferon and interleukin-2 prolong more than three times the survival of 26 consecutive endocrine dependent breast cancer patients with distant metastases: an exploratory trial.
Topics: Breast Neoplasms; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Immunotherapy; Interferon-beta; Interleukin-2; Letrozole; Multivariate Analysis; Neoplasm Metastasis; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Toremifene; Triazoles | 2005 |
Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Double-Blind Method; ErbB Receptors; Female; Humans; Letrozole; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Nitriles; Prognosis; Receptor, ErbB-2; Survival Analysis; Tamoxifen; Triazoles | 2006 |
Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Remission Induction; Triazoles | 1995 |
Phase II trial of anaxirone (TGU) in advanced colorectal cancer: an EORTC Early Clinical Trials Group (ECTG) study.
Topics: Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Thrombocytopenia; Treatment Outcome; Triazoles | 1994 |
A randomized phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Letrozole; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Survival Rate; Triazoles | 1997 |
Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
Topics: Aged; Aged, 80 and over; Aldosterone; Androgens; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Estrogens; Female; Follicle Stimulating Hormone; Humans; Hydrocortisone; Luteinizing Hormone; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 1995 |
80 other study(ies) available for triazoles and Metastase
| Article | Year |
|---|---|
Transcriptional network involving ERG and AR orchestrates Distal-less homeobox-1 mediated prostate cancer progression.
Topics: Androgen Antagonists; Animals; Azepines; Cell Line, Tumor; Disease Progression; Gene Expression Regulation, Neoplastic; Hepatocyte Nuclear Factor 3-alpha; Homeodomain Proteins; Humans; Male; Mice; Mice, Knockout; Mice, SCID; Neoplasm Metastasis; Oncogene Proteins, Fusion; Promoter Regions, Genetic; Prostate; Prostatic Neoplasms; Protein Binding; Receptors, Androgen; Serine Endopeptidases; Signal Transduction; Survival Analysis; Transcription Factors; Transcription, Genetic; Transcriptional Regulator ERG; Triazoles; Xenograft Model Antitumor Assays | 2021 |
The dicyano compound induces autophagic or apoptotic cell death via Twist/c-Myc axis depending on metastatic characteristics of breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Neoplasm Metastasis; Nuclear Proteins; Proto-Oncogene Proteins c-myc; Signal Transduction; Triazoles; Twist-Related Protein 1 | 2022 |
A Combination of an Antimitotic and a Bromodomain 4 Inhibitor Synergistically Inhibits the Metastatic MDA-MB-231 Breast Cancer Cell Line.
Topics: Antimitotic Agents; Antineoplastic Agents; Apoptosis; Azepines; Breast Neoplasms; Cell Cycle; Cell Cycle Proteins; Cell Proliferation; Estradiol; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mitosis; Neoplasm Metastasis; Nuclear Proteins; Proto-Oncogene Proteins c-myc; Sulfonamides; Transcription Factors; Triazoles | 2019 |
Combination of ACY-241 and JQ1 Synergistically Suppresses Metastasis of HNSCC via Regulation of MMP-2 and MMP-9.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azepines; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Metastasis; Neoplasm Proteins; Squamous Cell Carcinoma of Head and Neck; Triazoles | 2020 |
BRD4 inhibition boosts the therapeutic effects of epidermal growth factor receptor-targeted chimeric antigen receptor T cells in glioblastoma.
Topics: Animals; Azepines; Brain Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Combined Modality Therapy; Epigenesis, Genetic; ErbB Receptors; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Immunotherapy, Adoptive; Mice; Neoplasm Metastasis; Receptors, Chimeric Antigen; Transcription Factors; Triazoles; Xenograft Model Antitumor Assays | 2021 |
Inhibition of BRD4 suppresses tumor growth in prostate cancer via the enhancement of FOXO1 expression.
Topics: Aged; Aged, 80 and over; Animals; Azepines; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Forkhead Box Protein O1; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neoplasm Transplantation; Nuclear Proteins; Prostatic Neoplasms; Proto-Oncogene Proteins c-myc; RNA, Small Interfering; Transcription Factors; Triazoles; Up-Regulation | 2018 |
Design and development of Isatin-triazole hydrazones as potential inhibitors of microtubule affinity-regulating kinase 4 for the therapeutic management of cell proliferation and metastasis.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Hep G2 Cells; Humans; Hydrazones; Isatin; MCF-7 Cells; Neoplasm Metastasis; Oxidative Stress; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Triazoles | 2019 |
Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors.
Topics: Animals; Antineoplastic Agents; Azepines; BRCA1 Protein; BRCA2 Protein; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Mice; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Ovarian Neoplasms; Proteins; Proto-Oncogene Proteins c-myc; Triazoles; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2019 |
Modification and Biological Evaluation of a Series of 1,5-Diaryl-1,2,4-triazole Compounds as Novel Agents against Pancreatic Cancer Metastasis through Targeting Myoferlin.
Topics: Animals; Antineoplastic Agents; Calcium-Binding Proteins; Cell Line, Tumor; Cell Movement; Drug Design; Epithelial-Mesenchymal Transition; Humans; Membrane Proteins; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Muscle Proteins; Neoplasm Invasiveness; Neoplasm Metastasis; Pancreatic Neoplasms; Structure-Activity Relationship; Triazoles; Xenograft Model Antitumor Assays | 2019 |
Targeting heat shock protein 90 for the treatment of malignant pheochromocytoma.
Topics: Adrenal Gland Neoplasms; Adrenal Glands; Animals; Apoptosis; Benzoquinones; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cells, Cultured; Female; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Mice; Mice, Nude; Molecular Targeted Therapy; Neoplasm Metastasis; Pheochromocytoma; Rats; Triazoles | 2013 |
Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Apoptosis; CDC2 Protein Kinase; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cyclin B1; Dimerization; Humans; Imidazoles; Indoles; Intracellular Signaling Peptides and Proteins; M Phase Cell Cycle Checkpoints; Melanoma; Mice; Neoplasm Metastasis; Nocodazole; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-mdm2; Repressor Proteins; Sulfonamides; Triazoles; Tumor Suppressor Protein p53; Vemurafenib; Xenograft Model Antitumor Assays | 2013 |
Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation.
Topics: Androgens; Azepines; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Progression; Gene Expression Regulation, Neoplastic; Humans; Ligands; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-myc; Receptors, Androgen; Triazoles; Up-Regulation | 2013 |
Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors.
Topics: 5'-Nucleotidase; Adenosine A2 Receptor Antagonists; Animals; Cell Line, Tumor; Cytotoxicity, Immunologic; Flow Cytometry; Granzymes; Humans; Killer Cells, Natural; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Neoplasm Metastasis; Neoplasms, Experimental; Pyrimidines; Receptor, Adenosine A2A; Receptor, Adenosine A2B; Triazoles; Xanthines | 2013 |
The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Differentiation; Cell Growth Processes; Clinical Trials, Phase III as Topic; Female; Gene Expression Profiling; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies; Signal Transduction; Tamoxifen; Treatment Outcome; Triazoles | 2013 |
Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer.
Topics: Animals; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Disease Models, Animal; DNA Damage; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Female; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Mice; Mitosis; Neoplasm Metastasis; Neoplasm Staging; Positron-Emission Tomography; Tomography, X-Ray Computed; Triazoles; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2014 |
Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lapatinib; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Triazoles | 2014 |
Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer.
Topics: Animals; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Glucose Transporter Type 1; HSP90 Heat-Shock Proteins; Humans; Hypoxia-Inducible Factor 1; Immunoblotting; Immunohistochemistry; Mice; Mice, SCID; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplastic Stem Cells; Neovascularization, Pathologic; Neural Cell Adhesion Molecule L1; Reverse Transcriptase Polymerase Chain Reaction; Triazoles; Triple Negative Breast Neoplasms; Tumor Burden; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2014 |
Symptoms of endocrine treatment and outcome in the BIG 1-98 study.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Incidence; Letrozole; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Nitriles; Proportional Hazards Models; Retrospective Studies; Risk Factors; Tamoxifen; Time Factors; Treatment Outcome; Triazoles; Tumor Burden | 2014 |
[An elderly patient with advanced breast cancer who responded to treatment with letrozole-a case report].
Topics: Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Letrozole; Neoplasm Invasiveness; Neoplasm Metastasis; Nitriles; Triazoles | 2013 |
The CCL5/CCR5 axis contributes to the perineural invasion of human salivary adenoid cystic carcinoma.
Topics: Carcinoma, Adenoid Cystic; CCR5 Receptor Antagonists; Cell Line, Tumor; Cell Movement; Chemokine CCL5; Cyclohexanes; Humans; Maraviroc; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Peripheral Nerves; Receptors, CCR5; Salivary Gland Neoplasms; Triazoles | 2014 |
RapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of Pten-mutant metastasis.
Topics: Animals; Azepines; Gene Expression Regulation, Neoplastic; Genetic Vectors; HEK293 Cells; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neoplasm Metastasis; Neoplasms, Experimental; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; PTEN Phosphohydrolase; Retroviridae; Triazoles; Tumor Suppressor Protein p53 | 2014 |
Clinical and laboratory patterns during immune stimulation in hormone responsive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoembryonic Antigen; Cytokines; Disease Progression; Disease-Free Survival; Female; Humans; Immunity, Cellular; Immunotherapy; Interferon-beta; Interleukin-2; Letrozole; Middle Aged; Mucin-1; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Proportional Hazards Models; Selective Estrogen Receptor Modulators; T-Lymphocytes; Tamoxifen; Tissue Polypeptide Antigen; Toremifene; Triazoles | 2014 |
Case report: anti-hormonal therapy in the treatment of ductal carcinoma of the parotid gland.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Carcinoma, Ductal; Disease-Free Survival; Female; Humans; Neoplasm Metastasis; Nitriles; Parotid Neoplasms; Tamoxifen; Treatment Outcome; Triazoles | 2014 |
XPO1/CRM1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa).
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Movement; Exportin 1 Protein; Humans; Hydrazines; Karyopherins; Male; Mice, SCID; Neoplasm Metastasis; Osteoblasts; Prostatic Neoplasms; Receptors, Cytoplasmic and Nuclear; Triazoles; Xenograft Model Antitumor Assays | 2014 |
In silico design and biological evaluation of a dual specificity kinase inhibitor targeting cell cycle progression and angiogenesis.
Topics: Angiogenesis Inhibitors; Aniline Compounds; Animals; Breast Neoplasms; CDC2 Protein Kinase; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Design; Endothelial Cells; Female; Humans; Male; MCF-7 Cells; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Neovascularization, Pathologic; Neovascularization, Physiologic; Protein Kinase Inhibitors; Signal Transduction; Triazoles; Vascular Endothelial Growth Factor Receptor-2; Wound Healing | 2014 |
JQ1 suppresses tumor growth through downregulating LDHA in ovarian cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Azepines; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Isoenzymes; L-Lactate Dehydrogenase; Lactate Dehydrogenase 5; Membrane Potential, Mitochondrial; Mice; Necrosis; Neoplasm Metastasis; Neoplasms; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Proto-Oncogene Proteins c-myc; Reactive Oxygen Species; RNA Interference; Transcriptome; Triazoles | 2015 |
Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma.
Topics: Acetylation; Animals; Apoptosis; Azepines; Carcinoma, Merkel Cell; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Chromatin; Enhancer Elements, Genetic; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Humans; Jumonji Domain-Containing Histone Demethylases; Mice; Neoplasm Metastasis; Nuclear Proteins; Promoter Regions, Genetic; Protein Binding; Proto-Oncogene Proteins c-myb; Skin Neoplasms; Transcription Factors; Triazoles; Xenograft Model Antitumor Assays | 2015 |
Palbociclib for the Treatment of Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
Topics: Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Cyclin-Dependent Kinase 4; Disease-Free Survival; Drug Approval; Estrogen Receptor alpha; Female; Humans; Letrozole; Molecular Targeted Therapy; Neoplasm Metastasis; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Triazoles | 2015 |
Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression.
Topics: Animals; Apoptosis; CDC2 Protein Kinase; Cell Line, Tumor; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinases; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Oncogene Proteins; Ovarian Neoplasms; Oxazoles; RNA, Small Interfering; Thiazoles; Triazoles | 2015 |
Metastasis Suppressors Regulate the Tumor Microenvironment by Blocking Recruitment of Prometastatic Tumor-Associated Macrophages.
Topics: Animals; Cell Line, Tumor; Chemokine CCL5; Chemokines; Chemotaxis; Cyclohexanes; Disease-Free Survival; Female; Gene Expression Profiling; Gene Knockdown Techniques; Heterografts; HMGA2 Protein; Humans; Macrophages; Mammary Neoplasms, Experimental; Maraviroc; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Neoplasm Metastasis; Neoplasm Proteins; Phosphatidylethanolamine Binding Protein; Receptors, CCR5; RNA, Messenger; RNA, Neoplasm; Sequence Analysis, RNA; Triazoles; Triple Negative Breast Neoplasms; Tumor Microenvironment | 2015 |
Everolimus in Metastatic Breast Cancer: Clinical Experience as a Late Treatment Line.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case-Control Studies; Estradiol; Everolimus; Female; Follow-Up Studies; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Prognosis; Retrospective Studies; Survival Rate; Tamoxifen; Triazoles | 2015 |
Mesenchymal Cancer Cell-Stroma Crosstalk Promotes Niche Activation, Epithelial Reversion, and Metastatic Colonization.
Topics: Animals; Axl Receptor Tyrosine Kinase; Benzocycloheptenes; Breast Neoplasms; CD24 Antigen; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Epithelial-Mesenchymal Transition; Female; Homeodomain Proteins; Humans; Lung Neoplasms; Mice; Mice, Nude; Mice, Transgenic; Neoplasm Metastasis; Neoplastic Stem Cells; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; RNA Interference; Signal Transduction; Smad Proteins; Thrombospondins; Transforming Growth Factor beta; Transplantation, Heterologous; Triazoles | 2015 |
[Efficacies of aromatase inhibitors in the treatment of hormone dependent metastatic breast cancer in postmenopausal women: a report of 148 cases].
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Female; Hormones; Humans; Letrozole; Neoplasm Metastasis; Nitriles; Postmenopause; Triazoles | 2015 |
Endothelial Robo4 suppresses breast cancer growth and metastasis through regulation of tumor angiogenesis.
Topics: ADP-Ribosylation Factor 6; ADP-Ribosylation Factors; Animals; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; Down-Regulation; Endothelial Cells; Female; Gene Knockout Techniques; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Neovascularization, Pathologic; Nerve Tissue Proteins; Receptors, Cell Surface; Receptors, Immunologic; Signal Transduction; Triazoles; Vascular Endothelial Growth Factor A; Zonula Occludens-1 Protein | 2016 |
A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Canada; Cost-Benefit Analysis; Disease Progression; Female; Health Services; Humans; Lapatinib; Letrozole; Markov Chains; Models, Econometric; Neoplasm Metastasis; Nitriles; Quality-Adjusted Life Years; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Terminal Care; Trastuzumab; Triazoles | 2016 |
Lysophosphatidic acid activates Arf6 to promote the mesenchymal malignancy of renal cancer.
Topics: ADP-Ribosylation Factor 6; ADP-Ribosylation Factors; Adult; Aged; Aged, 80 and over; Amides; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Enzyme Inhibitors; Epithelial-Mesenchymal Transition; Female; GTP-Binding Protein alpha Subunits, G12-G13; Guanine Nucleotide Exchange Factors; HEK293 Cells; Humans; Immunohistochemistry; Indoles; Isoxazoles; Kidney Neoplasms; Lysophospholipids; Male; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Transplantation; Nerve Tissue Proteins; Propionates; Pyridines; Pyrroles; Receptors, Lysophosphatidic Acid; Signal Transduction; Sirolimus; Sunitinib; Triazoles | 2016 |
Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer.
Topics: AC133 Antigen; Anastrozole; Androstadienes; Animals; Antigens, CD; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cell Line, Tumor; Cell Self Renewal; Drug Resistance, Neoplasm; Estradiol; Female; Flow Cytometry; Fulvestrant; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; In Vitro Techniques; Interleukin-6; Letrozole; Leuprolide; MCF-7 Cells; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Neoplasm Transplantation; Neoplastic Stem Cells; Nitriles; Oxidative Phosphorylation; Peptides; Real-Time Polymerase Chain Reaction; Receptor, Notch3; Receptors, Estrogen; Receptors, Notch; Signal Transduction; Tamoxifen; Triazoles | 2016 |
Gas6/Axl Axis Contributes to Chemoresistance and Metastasis in Breast Cancer through Akt/GSK-3β/β-catenin Signaling.
Topics: Animals; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Benzocycloheptenes; beta Catenin; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Resistance; Gene Expression Profiling; Gene Silencing; Glycogen Synthase Kinase 3 beta; Heterografts; Humans; Intercellular Signaling Peptides and Proteins; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Receptor Protein-Tyrosine Kinases; Signal Transduction; Treatment Outcome; Triazoles | 2016 |
Integrated genetic and pharmacologic interrogation of rare cancers.
Topics: A549 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Line, Tumor; CRISPR-Cas Systems; Cyclin-Dependent Kinase 4; Doxorubicin; Drug Screening Assays, Antitumor; Exome; Exportin 1 Protein; Female; Genomics; Humans; Hydrazines; Karyopherins; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Transplantation; Piperazines; Pyridines; Rare Diseases; Receptors, Cytoplasmic and Nuclear; RNA Interference; Sarcoma; Sequence Analysis, RNA; Triazoles | 2016 |
Circulating oxysterol metabolites as potential new surrogate markers in patients with hormone receptor-positive breast cancer: Results of the OXYTAM study.
Topics: Adult; Aged; Androstadienes; Aromatase; Aromatase Inhibitors; Biomarkers; Body Mass Index; Breast Neoplasms; Cholestanes; Cholesterol; Feasibility Studies; Female; Gas Chromatography-Mass Spectrometry; Hormones; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Oxidative Stress; Oxysterols; Pilot Projects; Prognosis; Prospective Studies; Reproducibility of Results; Signal Transduction; Tamoxifen; Triazoles | 2017 |
Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer in Korea.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Republic of Korea; Survival Analysis; Treatment Outcome; Triazoles | 2017 |
Novel Triazole-Piperazine Hybrid Molecules Induce Apoptosis via Activation of the Mitochondrial Pathway and Exhibit Antitumor Efficacy in Osteosarcoma Xenograft Nude Mice Model.
Topics: Animals; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Mice; Mice, Nude; Mitochondria; Neoplasm Metastasis; Osteosarcoma; Piperazines; Triazoles; Xenograft Model Antitumor Assays | 2017 |
The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer.
Topics: Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Estrogens; Flow Cytometry; Humans; Letrozole; Neoplasm Metastasis; Nitriles; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptor, IGF Type 1; Signal Transduction; Triazoles | 2008 |
A paraneoplastic manifestation of metastatic breast cancer responding to endocrine therapy: a case report.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Creatine Kinase; Female; Humans; Immunoglobulin G; Middle Aged; Neoplasm Metastasis; Nitriles; Paraneoplastic Syndromes; Triazoles | 2008 |
Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma.
Topics: Aged; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Carcinoma; Disease Progression; Endometrial Hyperplasia; Endometrial Neoplasms; Endometrium; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Organ Size; Retrospective Studies; Time Factors; Triazoles | 2009 |
Hormonal therapy with letrozole prior to surgical management of recurrent metastatic low-grade endometrial stromal sarcoma (LGESS).
Topics: Antineoplastic Agents; Endometrial Neoplasms; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Sarcoma, Endometrial Stromal; Treatment Outcome; Triazoles | 2009 |
Aromatase inhibition in male breast cancer patients: biological and clinical implications.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms, Male; Carcinoma; Estradiol; Humans; Letrozole; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Retrospective Studies; Survival Analysis; Testosterone; Treatment Outcome; Triazoles | 2010 |
R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer.
Topics: Animals; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Benzocycloheptenes; Breast Neoplasms; Carcinoma; Female; HeLa Cells; Humans; K562 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Oncogene Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Survival Analysis; Triazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
Catastrophic squamous cell carcinoma in lung transplant patients treated with voriconazole.
Topics: Antifungal Agents; Carcinoma, Squamous Cell; Fatal Outcome; Female; Heart Transplantation; Humans; Lung Transplantation; Middle Aged; Mycoses; Neoplasm Invasiveness; Neoplasm Metastasis; Pyrimidines; Skin Neoplasms; Triazoles; Voriconazole | 2010 |
Effect of letrozole on plasma lipids, triglycerides, and estradiol in postmenopausal women with metastatic breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Estradiol; Estrogens; Female; Humans; Letrozole; Lipids; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Prospective Studies; Triazoles; Triglycerides | 2010 |
[A case of secondary inflammatory breast cancer with multiple metastases in which operation was possible through letrozole monotherapy].
Topics: Antineoplastic Agents; Biopsy, Needle; Carcinoma, Ductal, Breast; Catheter Ablation; Combined Modality Therapy; Female; Humans; Inflammatory Breast Neoplasms; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Positron-Emission Tomography; Triazoles | 2011 |
Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Aromatase; Breast Neoplasms; Disease Progression; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Polymorphism, Single Nucleotide; Triazoles | 2011 |
Effective role of hormonal therapy in metastatic primary neuroendocrine breast carcinoma.
Topics: Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Neuroendocrine; Diagnosis, Differential; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Pancreatic Neoplasms; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2011 |
1,2,4-Triazole D-ribose derivatives: design, synthesis and antitumoral evaluation.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; Ribose; Triazoles | 2012 |
CCR5 antagonist blocks metastasis of basal breast cancer cells.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; CCR5 Receptor Antagonists; Chemokine CCL5; Cyclohexanes; Female; Gene Expression Regulation, Neoplastic; Humans; Maraviroc; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Neoplasms, Basal Cell; Piperazines; Pyrimidines; Receptors, CCR5; Triazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2012 |
The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action.
Topics: Administration, Oral; Animals; Antigens, CD; Antineoplastic Agents; Apoptosis; Benzoates; Cell Cycle; Cell Line, Tumor; Copper; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Deferasirox; Female; Humans; Iron; Iron Chelating Agents; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Neuroectodermal Tumors, Primitive, Peripheral; Protein Serine-Threonine Kinases; Receptors, Transferrin; Small Cell Lung Carcinoma; Transplantation, Heterologous; Triazoles; Zinc | 2013 |
Letrozole's superiority over progestins and tamoxifen challenges standards of care in endocrine therapy for metastatic breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasm Metastasis; Nitriles; Progestins; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2002 |
Ultralow doses of various drugs in chemotherapy of experimental tumors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Indazoles; Leukemia P388; Lung Neoplasms; Melanoma; Mice; Mitomycin; Neoplasm Metastasis; Neoplasms, Experimental; Triazoles; Xenograft Model Antitumor Assays | 2003 |
[CHEMICAL AND PHARMACOLOGICAL STUDY OF NITROFURAZONE ANALOGUES WITH RESPECT TO THEIR THERAPEUTIC ACTION ON MALIGNANT EMBRYOMA OF THE TESTIS].
Topics: Antineoplastic Agents; Humans; Lung Neoplasms; Male; Mice; Neoplasm Metastasis; Neoplasms; Nitrofurazone; Pharmacology; Rats; Research; Teratoma; Testicular Neoplasms; Thiosemicarbazones; Triazoles | 1964 |
Superiority of letrozole over tamoxifen in the first-line treatment of metastatic breast cancer patients with normal serum Her-2/neu levels: question of tamoxifen resistance.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Estrogen Antagonists; Female; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Receptor, ErbB-2; Tamoxifen; Triazoles | 2003 |
[Complete remission obtained with letrozole in a man with metastatic breast cancer].
Topics: Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms, Male; Humans; Letrozole; Male; Neoplasm Metastasis; Nitriles; Remission Induction; Treatment Outcome; Triazoles | 2004 |
[Therapeutic effects of Anastrozole in patients with advanced and recurrent breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cholesterol; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Salvage Therapy; Survival Rate; Triazoles | 2004 |
Selected highlights from the 27th San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-11 December 2004.
Topics: Anastrozole; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Delivery Systems; Drug Therapy, Combination; Estradiol; Female; Fulvestrant; Gonadal Steroid Hormones; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Tamoxifen; Taxoids; Trastuzumab; Triazoles | 2005 |
Toxic epidermal necrolysis in patient with breast cancer receiving letrozole.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Fatal Outcome; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Stevens-Johnson Syndrome; Triazoles | 2006 |
Does survival increase in metastatic breast cancer with recently available anticancer drugs?
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Retrospective Studies; Survival Analysis; Tamoxifen; Triazoles | 2006 |
Plasma levels of tamoxifen, N-desmethyl tamoxifen and anastrozole in a patient with metastatic breast cancer and chronic hemodialysis.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Nitriles; Renal Dialysis; Tamoxifen; Triazoles | 2006 |
Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Cost-Benefit Analysis; Decision Support Techniques; Disease Progression; Female; Humans; Letrozole; Markov Chains; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Postmenopause; Quality-Adjusted Life Years; Tamoxifen; Time Factors; Triazoles; United States | 2006 |
Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Ovariectomy; Ovary; Premenopause; Receptors, Steroid; Triazoles | 2006 |
High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: a confirmatory prospective study.
Topics: Aromatase Inhibitors; Breast Neoplasms; Cohort Studies; Female; Humans; Letrozole; Neoplasm Metastasis; Nitriles; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome; Triazoles | 2007 |
[Efficacy of sequential treatment with anastrozole following exemestane compared with exemestane following anastrozole in patients with metastatic breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Nitriles; Retrospective Studies; Survival Rate; Triazoles | 2008 |
Augmentation of tumor metastasis by platelet-activating factor.
Topics: Animals; Antineoplastic Agents; Azepines; Female; Interleukin-1; Lung Neoplasms; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Platelet Activating Factor; Triazoles; Tumor Necrosis Factor-alpha | 1996 |
Anastrozole for metastatic breast cancer.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Neoplasm Metastasis; Nitriles; Triazoles | 1996 |
Aromatase inhibitors in metastatic breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Fadrozole; Female; Humans; Megestrol Acetate; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Tamoxifen; Triazoles | 1996 |
Inhibitory effect of radiosensitizer AK-2123 on experimental hepatic metastases and Ca2+ active transport.
Topics: Adenocarcinoma; Animals; Biological Transport, Active; Ca(2+) Mg(2+)-ATPase; Calcium; Colonic Neoplasms; Female; Liver Neoplasms; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Neoplasm Transplantation; Radiation-Sensitizing Agents; Triazoles | 1997 |
Effect of antiangiogenic agents on experimental animal models of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Cell Division; Cyclohexanes; Liver Neoplasms, Experimental; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Phenylalanine; Sesquiterpenes; Suramin; Thiophenes; Triazoles | 1999 |
Screening assay for promigratory/antimigratory compounds.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Screening Assays, Antitumor; Fluoresceins; Fluorescent Dyes; Humans; Neoplasm Metastasis; Propidium; Spectrometry, Fluorescence; Tamoxifen; Triazoles; Tumor Cells, Cultured | 2000 |
Letrozole for the treatment of pretreated advanced breast cancer patients: preliminary report.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Premenopause; Salvage Therapy; Treatment Outcome; Triazoles | 2000 |
Letrozole in second-line therapy of advanced breast cancer: more questions than answers.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Canada; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Europe; Female; Humans; Letrozole; Megestrol Acetate; Neoplasm Metastasis; Nitriles; Palliative Care; Postmenopause; Treatment Outcome; Triazoles | 2001 |
L651582: a novel antiproliferative and antimetastasis agent.
Topics: Aminoimidazole Carboxamide; Animals; Antineoplastic Agents; Cell Adhesion; Cell Division; Cell Movement; Female; GTP-Binding Proteins; Humans; Imidazoles; Mice; Neoplasm Metastasis; Phosphatidylinositols; Rats; Triazoles; Tumor Cells, Cultured | 1990 |
Phase II trial of 1,2,4-triglycidylurazol in patients with metastasized renal cell carcinoma.
Topics: Adult; Aged; Carcinoma, Renal Cell; Drug Evaluation; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Triazoles | 1987 |